Impact of organ-on-a-chip technology on pharmaceutical R&D costs

Nora Franzen, W. H. van Harten, Valesca P. Retèl, P. Loskill, J. van den Eijnden-van Raaij, Maarten IJzerman*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

6 Citations (Scopus)
32 Downloads (Pure)


Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.

Original languageEnglish
Pages (from-to)1720-1724
Number of pages5
JournalDrug discovery today
Issue number9
Early online date8 Jun 2019
Publication statusPublished - 1 Sep 2019

Fingerprint Dive into the research topics of 'Impact of organ-on-a-chip technology on pharmaceutical R&D costs'. Together they form a unique fingerprint.

  • Cite this